The YUMAB® platform provides all technologies for a fully integrated human antibody development in one company. We offer individually designed, work package-based contract research projects – from your target molecule to your engineered and optimized antibody lead candidate. Single technology modules or combinations thereof are also available as R&D service to assist your antibody program at every stage. The core technologies of the platform are Hit Discovery, Lead Engineering, Lead Development.

Usually, the optimization of the initial antibody candidates is necessary for the development of therapeutic antibodies. The YUMAB platform provides two in-vitro evolution technologies for the optimization of the antibody’s affinity, stability, specificity or selectivity: in-vitro evolution by YUlight shuffling and in-vitro evolution by mutagenesis.

Additionally, in-silico analysis can be applied to identify and optimize antibodies with the best developability score.

The YUMAB® humanization platform provides two technologies for the humanization of animal-derived antibodies of any source (B-cells, Hybridoma cultures, antibody sequences) by Germline-optimized CDR grafting and Template-driven chain shuffling.

The humanized antibodies can be directly used for further optimization by lead discovery and lead development.